Lack of prognostic significance of survivin, survivin-ΔEx3, survivin-2B, galectin-3, bag-1, bax-α and MRP-1 mRNAs in breast cancer

Cancer Letters

Volumn 201, Issue 2, 2003, Pages 225-236

  O'Driscoll, Lorraine ^a   Linehan, Rasha ^a   Kennedy, Susan M ^b,c   Cronin, Deirdre ^a   Purcell, Rachel ^b,c   Glynn, Sharon ^a   McDermott, Enda W ^c   Hill, Arnold D ^c   O'Higgins, Niall J ^c   Parkinson, Michael ^a   Clynes, Martin ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b Dept Otolaryngol Hd Neck Surg   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Breast cancer; Disease relapse free survival; Multiple drug resistance; Overall survival; Reverse transcriptase polymerase chain reaction

Indexed keywords

APOPTOSIS INHIBITOR; BAG 1 PROTEIN; GALECTIN 3; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; SURVIVIN; SURVIVIN 2B; SURVIVIN EX3; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0242352518     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00518-4     Document Type: Article

References (38)

1. Miller L.K. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell. Biol. 9:1999;323-328.
2. Altieri D.C., Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 79:1999;1327-1333.
3. Reed J.C., Reed S.I. Survivin' cell-separation anxiety. Nat. Cell. Biol. 1:1999;E199-E200.
4. O'Driscoll L., Linehan R., Clynes M. Survivin: role in normal cells and in pathological conditions. Curr. Can. Drug Targets. 3:2003;131-152.
5. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7:2001;542-547.
6. Verhagen A.M., Coulson E.J., Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2:2001;. Reviews 3009.
7. Lu C.D., Altieri D.C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumour cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58:1998;1808-1812.
8. Grossman D., McNiff J.M., Li F., Altieri D.C. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab. Invest. 79:1999;1121-1126.
9. Okada E., Murai Y., Matsui K., Isizawa S., Cheng C., Masuda M., Takano Y. Survivin expression in tumour cell nuclei is predictive of a favourable prognosis in gastric cancer patients. Cancer Lett. 163:2001;109-116.
10. Kennedy S.M., O'Driscoll L., Purcell R., Fitz-Simons N., Mc Dermot E.W., Hill A.D., O'Higgins N.J., Parkinson M., Clynes M. Prognostic importance of survivin in breast cancer. Br. J. Cancer. 88:2003;1077-1083.
11. Mahotka C., Wenzel M., Springer E., Gabbert H.E., Gerharz C.D. Survivin-ΔEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59:1999;6097-6102.
12. Mahotka C., Krieg T., Krieg A., Wenzel M., Suschek C.V., Heydthausen M., Gabbert H.E., Gerharz C.D. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int. J. Cancer. 100:2002;30-36.
13. Krieg A., Mahotka C., Krieg T., Grabsch H., Muller W., Takeno S., Suschek C.V., Heydthausen M., Gabbert H.E., Gerharz C.D. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br. J. Cancer. 86:2002;737-743.
14. Kappler M., Kohler T., Kampf C., Diestelkotter P., Wurl P., Schmitz M., Bartel F., Lautenschlager C., Rieber E.P., Schmidt H., Bache M., Taubert H., Meye A. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int. J. Cancer. 95:2001;360-363.
15. Castronovo V., Van den Brule F.A., Jackers P., Clausse N., Liu F.T., Gillet C., Sobel M.E. Decreased expression of galectin-3 is associated with progression of human breast cancer. J. Pathol. 179:1996;43-48.
16. Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int. J. Oncol. 12:1998;1287-1290.
17. Castiglione F., Sarotto I., Fontana V., Destefanis M., Venturino A., Ferro S., Cardaropoli S., Orengo M.A., Porcile G. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients, Anticancer Res. 19:1999;4555-4563.
18. Ciocca D.R., Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine. 13:2000;1-10.
19. Tang S.C., Shehata N., Chernenko G., Khalifa M., Wang X., Shaheta N. Expression of Bag-1 in invasive breast carcinomas. J. Clin. Oncol. 17:1999;1710-1719.
20. Bargou R.C., Wagener C., Bommert K., Mapara M.Y., Daniel P.T., Arnold W., Dietel M., Guski H., Feller A., Royer H.D., Dorken B. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumour growth in SCID mice. J. Clin. Invest. 97:1996;2651-2659.
21. Filipits M., Malayeri R., Suchomel R.W., Pohl G., Stranzl T., Dekan G., Kaider A., Stiglbauer W., Depisch D., Pirker R. Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res. 19:1999;5043-5049.
22. Kim R., Nishimoto N., Osaki A., Kojima J., Fujii S., Inai K., Toge T. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery. Breast Cancer. 8:2001;146-152.
23. Page D.L., Anderson T.J. Diagnostic Histopathology of the Breast. 1987;Churchill, London.
24. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:1991;403-410.
25. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumours. sixth ed. 2002;Wiley, New York. pp. 131-141.
26. Azuhata T., Scott D., Takamizawa S., Wen J., Davidoff A., Fukuzawa M., Sandler A. Inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J. Pediat. Surg. 36:2001;1785-1791.
27. Tajiri T., Tanaka S., Shono K., Kinoshita Y., Fujii Y., Suita S., Ihara K., Hara T. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett. 166:2001;89-94.
28. Sandler A., Scott D., Azuhata T., Takamizawa S., O'Dorisio S. The survivin: Fas ratio is predictive of recurrent disease in neuroblastoma. J. Ped. Surg. 37:2002;507-511.
29. Sarela A.I., Macadam R.C.A., Farmery S.M., Guillou P.J. Survivin, a novel inhibitor of apoptosis, and prognosis in colorectal carcinoma. Br. J. Surg. 85:1998;1555-1593.
30. Sarela A.I., Macadam R.C.A., Farmery S.M., Markham A.F., Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 46:2000;645-650.
31. Kato J., Kuwabara Y., Mitani M., Shinoda N., Sato A., Toyama T., Mitsui A., Nishiwaki T., Moriyama S., Kudo J., Fujii Y. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer. 95:2001;92-95.
32. Ikeguchi M., Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br. J. Cancer. 87:2002;883-887.
33. Takamizawa S., Scott D., Wen J., Grundy P., Bishop W., Kimura K., Sandler A. The survivin:Fas ratio in pediatric renal tumours. J. Pediatr. Surg. 36:2001;37-42.
34. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., Takase K., Moriyama M., Kawano H., Hayashida M., Nakano T., Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 31:2000;1080-1085.
35. Monzo M., Rosell R., Felip E., Astudillo J., Sanchez J.J., Maestre J., Martin C., Font A., Barnadas A., Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17:1999;2100-2104.
36. Nasu S., Yagihashi A., Izawa A., Saito K., Asanuma K., Nakamura M., Kobayashi D., Okazaki M., Watanabe N. Survivin mRNA expression in patients with breast cancer. Anticancer Res. 22:2002;1839-1843.
37. Ikeguchi M., Kaibara N. Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer. Int. J. Mol. Med. 8:2001;661-666.
38. Sjostrom J., Blomqvist C., Von Boguslawski K., Bengtsson N.O., Mjaaland I., Malmstrom P., Ostenstadt B., Wist E., Valvere V., Takayama S., Reed J.C., Saksela E. The predictive value of bcl-2, bax, bcl-XL, bag-1, fas and fasL for chemotherapy response in advanced breast cancer. Clin. Cancer Res. 8:2002;811-816.